Velasquez Daniel E, Wang Yuhuan, Jiang Baoming
a Division of Viral Diseases ; Centers for Disease Control and Prevention ; Atlanta , GA USA.
Hum Vaccin Immunother. 2015;11(2):531-3. doi: 10.4161/21645515.2014.988553.
To improve lower efficacy among infants in low income countries and the safety (e.g., rare but severe intussusception) of live oral rotavirus vaccines, we have developed CDC-9 strain with G1P[8] specificity as a candidate inactivated rotavirus vaccine (IRV). This IRV of 3 doses elicits high titers of IgG, neutralizing activity to homotypic and heterotypic human strains and IgG avidity in guinea pigs, thus is a promising alternative to enhance global immunization against rotavirus in children.
为提高低收入国家婴儿中现有疫苗效力较低的问题以及口服轮状病毒活疫苗的安全性（如罕见但严重的肠套叠），我们已开发出具有G1P[8]特异性的CDC-9株作为候选灭活轮状病毒疫苗（IRV）。这种3剂次的IRV在豚鼠中可引发高滴度的IgG、对同型和异型人类毒株的中和活性以及IgG亲和力，因此是增强全球儿童轮状病毒免疫接种的一种有前景的替代方案。
